Last quarter (Q4 2023), Chemomab Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Chemomab Therapeutics's net income was $―. See Chemomab Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	-	-
Cost of Revenue	$ -5.22M	-	$ 5.14M	$ -3.31M	$ 1.18M	-
Gross Profit	$ 5.22M	-	$ -5.14M	$ 3.31M	$ 1.18M	-
Operating Expense	$ -1.92M	$ 25.46M	$ 28.53M	$ -12.37M	$ -5.97M	$ -19.55M
Operating Income	$ -26.01M	$ -25.46M	$ -28.53M	$ -12.37M	$ -5.97M	$ -19.55M
Net Non Operating Interest Income Expense	$ 353.00K	$ 1.24M	-	-	-	$ 9.00K
Other Income Expense	$ -17.00K	-	$ -353.00K	$ -345.00K	$ 500.00K	$ 4.57M
Pretax Income	$ -24.86M	$ -24.22M	$ -28.18M	$ -12.37M	$ -5.97M	$ -22.90M
Tax Provision	$ 31.00K	-	$ -534.00K	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -25.90M	$ -24.22M	$ -27.65M	$ -12.48M	$ -5.95M	$ -18.67M
Basic EPS	$ -0.61	$ -0.10	$ 0.12	-	-	-
Diluted EPS	$ -0.63	$ -0.10	$ 0.12	$ 0.06	$ 0.64	$ 12.64
Basic Average Shares	$ 460.02M	$ 235.00M	$ 227.59M	$ 207.47M	$ 8.55M	$ 2.15K
Diluted Average Shares	$ 460.02M	$ 235.00M	$ 227.59M	$ 207.97M	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -7.14M	$ 25.46M	$ -33.76M	$ -15.68M	$ -4.79M	$ -19.55M
Net Income From Continuing And Discontinued Operation	$ -25.59M	$ -24.22M	$ -27.65M	$ -12.48M	$ -5.95M	$ -18.67M
Normalized Income	$ -8.08M	-	-	-	-	-
Interest Expense	-	-	-	-	-	-
EBIT	$ -25.09M	-	$ -28.18M	$ -12.37M	$ -5.97M	$ -22.91M
EBITDA	$ -25.05M	-	$ -28.12M	$ -12.33M	-	-

Currency in USD

Chemomab Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing